Literature DB >> 7689452

Synergy and antagonism of fluoroquinolones with other classes of antimicrobial agents.

H C Neu1.   

Abstract

In an attempt to overcome some of the gaps in their antibacterial spectrum, e.g. some Gram-positive bacteria (notably streptococci and Streptococcus pneumoniae) and anaerobes, the fluoroquinolones have been combined with other bactericidal and bacteriostatic agents. In general, the fluoroquinolones rarely show either synergy or antagonism when used in combination with other antimicrobial agents against most bacteria. Therefore, in infections where the fluoroquinolones do not provide cover against all potential organisms, combined treatment with an appropriate agent may be considered. Current data suggest that the fluoroquinolones are not antagonistic with beta-lactams, macrolides, clindamycin and the imidazoles. Aminoglycosides in combination with the fluoroquinolones do not show synergy. Antipseudomonal penicillins, ceftazidime or imipenem in combination with the fluoroquinolones are synergistic and may be useful for treating infections in immunocompromised patients. Rifampicin in combination with a fluoroquinolone for the treatment of staphylococcal endocarditis or osteomyelitis may be useful, although in vitro and in vivo results do not always coincide.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 7689452     DOI: 10.2165/00003495-199300453-00011

Source DB:  PubMed          Journal:  Drugs        ISSN: 0012-6667            Impact factor:   9.546


  46 in total

1.  Susceptibility of Mycobacterium kansasii to ethambutol and its combination with rifamycins, ciprofloxacin and isoniazid.

Authors:  U Hjelm; J Kaustová; M Kubín; S E Hoffner
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1992-01       Impact factor: 3.267

2.  Ciprofloxacin, azlocillin, ceftizoxime and amikacin alone and in combination against gram-negative bacilli in an infected chamber model.

Authors:  D M Bamberger; L R Peterson; D N Gerding; J A Moody; C E Fasching
Journal:  J Antimicrob Chemother       Date:  1986-07       Impact factor: 5.790

3.  Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations.

Authors:  S M Smith; R H Eng; F Tecson-Tumang
Journal:  Antimicrob Agents Chemother       Date:  1989-02       Impact factor: 5.191

4.  In vitro antibacterial activity of imipenem in combination with newer quinolone derivatives.

Authors:  W Kern; H Gulden; E Vanek; E Kurrle
Journal:  Chemotherapy       Date:  1988       Impact factor: 2.544

5.  Synergistic interactions of ciprofloxacin and extended-spectrum beta-lactams or aminoglycosides against multiply drug-resistant Pseudomonas maltophilia.

Authors:  A W Chow; J Wong; K H Bartlett
Journal:  Antimicrob Agents Chemother       Date:  1988-05       Impact factor: 5.191

6.  Treatment of methicillin-resistant Staphylococcus aureus experimental osteomyelitis with ciprofloxacin or vancomycin alone or in combination with rifampin.

Authors:  N K Henry; M S Rouse; A L Whitesell; M E McConnell; W R Wilson
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

7.  In vitro susceptibility of Mycobacterium tuberculosis to ofloxacin and ciprofloxacin in combination with rifampin and isoniazid.

Authors:  M Casal; J Gutierrez; J González; P Ruiz
Journal:  Chemioterapia       Date:  1987-12

8.  Activity of ciprofloxacin and other fluorinated quinolones against mycobacteria.

Authors:  L S Young; O G Berlin; C B Inderlied
Journal:  Am J Med       Date:  1987-04-27       Impact factor: 4.965

9.  Susceptibility of anaerobic bacteria isolated from intra-abdominal infections to ofloxacin and interaction of ofloxacin with metronidazole.

Authors:  E J Goldstein; D M Citron
Journal:  Antimicrob Agents Chemother       Date:  1991-11       Impact factor: 5.191

10.  Serum bactericidal activity of rifampin in combination with other antimicrobial agents against Staphylococcus aureus.

Authors:  C J Hackbarth; H F Chambers; M A Sande
Journal:  Antimicrob Agents Chemother       Date:  1986-04       Impact factor: 5.191

View more
  3 in total

Review 1.  Combination therapy for treatment of infections with gram-negative bacteria.

Authors:  Pranita D Tamma; Sara E Cosgrove; Lisa L Maragakis
Journal:  Clin Microbiol Rev       Date:  2012-07       Impact factor: 26.132

2.  [Antimicrobial combination therapy].

Authors:  Günter Weiss
Journal:  Wien Med Wochenschr       Date:  2003

Review 3.  An alternate pathophysiologic paradigm of sepsis and septic shock: implications for optimizing antimicrobial therapy.

Authors:  Anand Kumar
Journal:  Virulence       Date:  2013-11-01       Impact factor: 5.882

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.